District Court: State Law Tort Claims Involving Class II De Novo Device Are Expressly Preempted

Oops! Subscribers must be logged in to access this content.

Not A Thompson FDA Subscriber?

Unlock access to the benefits below with a no-cost, risk-free trial of the FDA Compliance Expert Suite.

Subscription Benefits

Start Your Free Trial

By signing up for a tour of the Thompson FDA Compliance Expert Suite, you are also registering to receive email offers and product updates from us. Simply click unsubscribe at the bottom of any email if you would like to discontinue delivery.

District Court: State Law Tort Claims Involving Class II De Novo Device Are Expressly Preempted

Dennis Tosh

July 31, 2024 at 06:13 PM EST

A federal district court in Louisiana has held that state law tort claims brought against the manufacturer of a Class II medical device authorized for marketing through the FDA’s de novo classification pathway were expressly preempted (Dickson v. Dexcom Inc., No. 2:24-cv-00121, 2024 U.S. Dist. LEXIS 124572, 2024 WL 3417392 (W.D. La. July 15, 2024)). Dexcom Inc. submitted a de... Read More

My Research Folders

You are not Logged in yet, Please login to see Your research folders.

Oops! Subscribers must be logged in to access this content.

Not A Thompson FDA Subscriber?

Unlock access to the benefits below with a no-cost, risk-free trial of the FDA Compliance Expert Suite.

Subscription Benefits

Start Your Free Trial

District Court: State Law Tort Claims Involving Class II De Novo Device Are Expressly Preempted

My Research Folders

THOMPSON FDA

COMPLIANCE EXPERT

RESOURCES

HELP

CONTACT